REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

24/03/2016 15:00

RNS Number : 2424T
AstraZeneca PLC
24 March 2016
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities, were granted awards over the Company's ordinary shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Investment Plan (AZIP). Two ADSs equal one ordinary share.
Name
Shares awarded under AZDBP
Shares awarded under AZPSP
Shares awarded under AZIP
Award price per share
Pascal Soriot
17,352
129,713
21,618
3923p
Marc Dunoyer
8,798
54,101
9,016
3923p
Sean Bohen
1,496
78,155
13,025
$28.19
Luke Miels
2,107
30,225
5,037
3923p
The AZDBP award represents the portion of each individual's annual bonus for 2015 that they are required to defer into shares. The shares are subject to a three-year holding period (24 March 2016 to 23 March 2019).
The AZPSP award is subject to a combination of performance measures focused on our scientific, commercial and financial performance assessed over a three-year performance period (1 January 2016 to 31 December 2018). The award will vest on the third anniversary of the date on which it was granted, except for awards to Executive Directors, which will be subject to a further two-year holding period before the award vests.
The AZIP award is subject to two performance hurdles relating to dividend and dividend cover over a four-year performance period (1 January 2016 to 31 December 2019). The award is subject to a four-year holding period, commencing at the end of the performance period.
Details of the performance measures that relate to the AZPSP and AZIP awards can be found in the Directors' Remuneration Report of the AstraZeneca Annual Report and Form 20-F Information 2015 which is available on the Company's website at www.astrazeneca-annualreports.com/2015/.
A C N Kemp
Company Secretary
24 March 2016

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSUSASRNUAOUAR